U.S. markets close in 5 hours 52 minutes

Prelude Therapeutics Incorporated (PRLD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.31-0.06 (-0.81%)
As of 10:08AM EDT. Market open.

Prelude Therapeutics Incorporated

200 Powder Mill Road
Wilmington, DE 19803
United States
302 467 1280

Full Time Employees112

Key Executives

NameTitlePayExercisedYear Born
Dr. Krishna Vaddi D.V.M., Ph.D.Founder, CEO & Director809.88kN/A1966
Dr. Peggy A. Scherle Ph.D.Chief Scientific Officer564.27kN/A1961
Dr. Andrew P. Combs Ph.D.Exec. VP & Head of Chemistry562.46kN/A1966
Dr. Edna Huang M.D.Pres & Chief Medical OfficerN/AN/A1973
Mr. Laurent ChardonnetChief Financial OfficerN/AN/A1965
Ms. Aimee Crombie Ph.D.Sr. VP and Head of Strategic Planning & OperationsN/AN/AN/A
Dr. Madhu Pudipeddi Ph.D.Sr. VP of Technical OperationsN/AN/AN/A
Ms. Michele Porreca M.B.A.Chief People OfficerN/AN/AN/A
Mr. Naveen Babbar Ph.D.Sr. VP of Translation MedicineN/AN/AN/A
Dr. Neelesh Sharma M.D., Ph.D.Sr. VP of Clinical Devel.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Corporate Governance

Prelude Therapeutics Incorporated’s ISS Governance QualityScore as of October 1, 2022 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 9; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.